Coxsackievirus B3-Its Potential as an Oncolytic Virus.
Ontology highlight
ABSTRACT: Oncolytic virotherapy represents one of the most advanced strategies to treat otherwise untreatable types of cancer. Despite encouraging developments in recent years, the limited fraction of patients responding to therapy has demonstrated the need to search for new suitable viruses. Coxsackievirus B3 (CVB3) is a promising novel candidate with particularly valuable features. Its entry receptor, the coxsackievirus and adenovirus receptor (CAR), and heparan sulfate, which is used for cellular entry by some CVB3 variants, are highly expressed on various cancer types. Consequently, CVB3 has broad anti-tumor activity, as shown in various xenograft and syngeneic mouse tumor models. In addition to direct tumor cell killing the virus induces a strong immune response against the tumor, which contrib
SUBMITTER: Geisler A
PROVIDER: S-EPMC8143167 | biostudies-literature | 2021 Apr
REPOSITORIES: biostudies-literature
ACCESS DATA